(NASDAQ: ODTX) Odyssey Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.88%.
Odyssey Therapeutics's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast ODTX's earnings for 2026 to be -$238,480,829, with the lowest ODTX earnings forecast at -$256,680,593, and the highest ODTX earnings forecast at -$226,067,311. On average, 7 Wall Street analysts forecast ODTX's earnings for 2027 to be -$221,323,934, with the lowest ODTX earnings forecast at -$226,067,311, and the highest ODTX earnings forecast at -$210,928,875.
In 2028, ODTX is forecast to generate -$221,569,033 in earnings, with the lowest earnings forecast at -$222,770,496 and the highest earnings forecast at -$221,525,780.